Cambridge, United States
AVROBIO is a United States-based, clinical-stage biotechnology company founded in 2015. With its headquarters in Cambridge, Mass., the firm is advancing the field of gene therapy with its proprietary plato® platform.
Driven by the slogan, "Clinical-stage lentiviral gene therapy company, powered by plato®. Our vision: bring personalized gene therapy worldwide," AVROBIO is targeting the root cause of genetic diseases. Its innovative approach involves introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs). The company’s pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease.
The company's recent financial history includes a $60.00M Series B investment on 01 February 2018, secured from notable investors such as Atlas Venture, SV Health Investors, and Citadel, among others. This underlines investor confidence in its scalable gene therapy technology aimed at global commercialization.
